Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).

被引：44

作者：

Bendell, Johanna C.

Powderly, John D.

Lieu, Christopher Hanyoung

Eckhardt, S. Gail

Hurwitz, Herbert

Hochster, Howard S.

Murphy, Janet E.

Funke, Roel Peter

Rossi, Cheryl

Wallin, Jeffrey

Waterkamp, Daniel

Pishvaian, Michael J.

机构：

[1] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA

[2] Carolina BioOncol Inst, Huntersville, NC USA

[3] Univ Colorado, Denver, CO 80202 USA

[4] Univ Colorado, Sch Med, Aurora, CO USA

[5] Duke Univ, Med Ctr, Durham, NC USA

[6] Yale Univ, Sch Med, Dept Med Oncol, New Haven, CT USA

[7] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[8] Genentech Inc, San Francisco, CA 94080 USA

[9] F Hoffmann La Roche Ltd, Basel, Switzerland

[10] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA

来源：

关键词：

D O I：

10.1200/jco.2015.33.3_suppl.704

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

704

引用

页数：1